Theriva biologics reports fourth quarter and full-year 2022 operational highlights and financial results

– dosed the first patient in virage, a phase 2b clinical trial of systemically administered vcn-01 in combination with chemotherapy for pancreatic ductal adenocarcinoma –

TOVX Ratings Summary

TOVX Quant Ranking